FDA approves first treatment drug for long-chain fatty acid oxidation metabolic disease - Dojolvi
-
Last Update: 2020-07-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Ultragenyx, a maker of rare disease drugs, has announced that its new drug Crysvita for metabolic disorders has been approved by theFDAfor the treatment of long-chain fatty acid oxidation metabolic disease (LC-FAOD)ultragenyx, a manufacturer of rare diseases, has announced that its new drug, Dojolvi (triamcinolone, ) for metabolic disorders has been approved by the FDA for the treatment of long-chain fatty acid oxidation metabolic disease (LC-FAOD), which cannot convert fatty acids into energyDojolvi is a synthetic midchain triglycerides that provide energy for patients who are unable to metabolize long-chain fatty acids themselves, including beneficial omega-3 fatty acidsExtreme consumption of glucose in the body can lead to hospitalization or even deaththe drugmaker says the disease is believed to affectof 2,000 to 3,500 U.Schildren each yearaccording to Ultragenyx CEO Emil Kakkis, Dojolvi's unique mechanism of action will change the lives of family patients who rely on restrictive diets to alleviate symptoms
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.